JP2020526526A - アデノシン誘導体を含む糖尿病性腎症の予防及び治療用薬学的組成物 - Google Patents
アデノシン誘導体を含む糖尿病性腎症の予防及び治療用薬学的組成物 Download PDFInfo
- Publication number
- JP2020526526A JP2020526526A JP2020500619A JP2020500619A JP2020526526A JP 2020526526 A JP2020526526 A JP 2020526526A JP 2020500619 A JP2020500619 A JP 2020500619A JP 2020500619 A JP2020500619 A JP 2020500619A JP 2020526526 A JP2020526526 A JP 2020526526A
- Authority
- JP
- Japan
- Prior art keywords
- diabetic nephropathy
- prevention
- treatment
- substituted
- chemical formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (9)
- 下記化学式1で表される化合物またはその薬学的に許容可能な塩を有効成分として含む糖尿病性腎症の予防または治療用薬学的組成物。
Aは、OまたはSであり、
Rは、非置換されるか、独立して、または選択的に1または2以上のC6〜C10のアリールで置換された直鎖状または側鎖状のC1〜C5のアルキル、非置換されるか、独立して、または選択的にハロゲン及び直鎖状または側鎖状のC1〜C4のアルコキシ基が、1または2以上に置換されたベンジルまたはヒドロキシカルボニルで置換されたベンジルであり、
Yは、Hまたはハロゲン元素である)。 - 前記糖尿病性腎症は、1型糖尿病及び2型糖尿病のうち1つ以上によることである請求項1に記載の糖尿病性腎症の予防または治療用薬学的組成物。
- 前記化学式1で表される化合物は、下記化学式Bで表される化合物である請求項1に記載の糖尿病性腎症の予防または治療用薬学的組成物。
[化B]
- 下記化学式1で表される化合物またはその薬学的に許容可能な塩を含む糖尿病性腎症の予防または治療用経口投与剤。
[化1]
Aは、OまたはSであり、
Rは、非置換されるか、独立して、または選択的に1または2以上のC6〜C10のアリールで置換された直鎖状または側鎖状のC1〜C5のアルキル、非置換されるか、独立して、または選択的にハロゲン及び直鎖状または側鎖状のC1〜C4のアルコキシ基が、1または2以上に置換されたベンジルまたはヒドロキシカルボニルで置換されたベンジルであり、
Yは、Hまたはハロゲン元素である)。 - 前記糖尿病性腎症は、1型糖尿病及び2型糖尿病のうち1つ以上によることである請求項4に記載の糖尿病性腎症の予防または治療用経口投与剤。
- 前記経口投与剤は、メチルセルロース(MC)、ジメチルスルホキシド(DMSO)、ポリエチレングリコール(PEG)及び蒸留水からなる群から選択される1つ以上の賦形剤をさらに含む請求項4に記載の糖尿病性腎症の予防または治療用経口投与剤。
- 前記経口投与剤は、賦形剤として0.5wt%メチルセルロースを含む請求項6に記載の糖尿病性腎症の予防または治療用経口投与剤。
- 前記化学式1で表される化合物またはその薬学的に許容可能な塩は、粉末状にカプセル内に充填される請求項4に記載の糖尿病性腎症の予防または治療用経口投与剤。
- 前記化学式1で表される化合物は、下記化学式Bで表される化合物である請求項4に記載の糖尿病性腎症の予防または治療用経口投与剤。
[化B]
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021171570A JP2022017355A (ja) | 2017-07-07 | 2021-10-20 | アデノシン誘導体を含む糖尿病性腎症の予防及び治療用薬学的組成物 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2017-0086703 | 2017-07-07 | ||
KR1020170086703A KR101820909B1 (ko) | 2017-07-07 | 2017-07-07 | 아데노신 유도체를 포함하는 만성신장질환 예방 및 치료용 약학적 조성물 |
PCT/KR2018/007717 WO2019009674A1 (ko) | 2017-07-07 | 2018-07-06 | 아데노신 유도체를 포함하는 당뇨병성 신증 예방 및 치료용 약학적 조성물 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021171570A Division JP2022017355A (ja) | 2017-07-07 | 2021-10-20 | アデノシン誘導体を含む糖尿病性腎症の予防及び治療用薬学的組成物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2020526526A true JP2020526526A (ja) | 2020-08-31 |
JP6965429B2 JP6965429B2 (ja) | 2021-11-10 |
Family
ID=61071116
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020500619A Active JP6965429B2 (ja) | 2017-07-07 | 2018-07-06 | アデノシン誘導体を含む糖尿病性腎症の予防及び治療用薬学的組成物 |
JP2021171570A Pending JP2022017355A (ja) | 2017-07-07 | 2021-10-20 | アデノシン誘導体を含む糖尿病性腎症の予防及び治療用薬学的組成物 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021171570A Pending JP2022017355A (ja) | 2017-07-07 | 2021-10-20 | アデノシン誘導体を含む糖尿病性腎症の予防及び治療用薬学的組成物 |
Country Status (8)
Country | Link |
---|---|
US (2) | US11266644B2 (ja) |
EP (2) | EP3650029B1 (ja) |
JP (2) | JP6965429B2 (ja) |
KR (1) | KR101820909B1 (ja) |
CN (2) | CN110869030B (ja) |
AU (1) | AU2018297009B2 (ja) |
CA (1) | CA3069118C (ja) |
WO (1) | WO2019009674A1 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101805400B1 (ko) * | 2017-03-21 | 2017-12-07 | 퓨쳐메디신 주식회사 | 아데노신 유도체를 포함하는 녹내장 예방 및 치료용 약학적 조성물 |
KR101820909B1 (ko) * | 2017-07-07 | 2018-01-23 | 퓨쳐메디신 주식회사 | 아데노신 유도체를 포함하는 만성신장질환 예방 및 치료용 약학적 조성물 |
KR102667692B1 (ko) * | 2020-12-11 | 2024-05-21 | 서울대학교산학협력단 | 1'-호모아데노신 유도체 및 이를 유효성분으로 포함하는 저아디포넥틴혈증 관련 질환의 예방 또는 치료용 약학 조성물 |
KR20240013997A (ko) * | 2022-07-22 | 2024-01-31 | 서울대학교산학협력단 | 아데노신 수용체에 작용하는 리간드 내지 이를 포함하는 비만 예방, 개선 또는 치료용 조성물 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101323413B1 (ko) * | 2012-07-26 | 2013-10-29 | 이화여자대학교 산학협력단 | (2r,3r,4s)-2-(2-클로로-6-(3-아이도벤질아미노)-9h-퓨린-9-일)-테트라하이드로싸이오펜-3,4-다이올 및 이의 유도체를 포함하는 만성신장질환 예방 또는 치료용 약학적 조성물 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1578758A4 (en) * | 2002-10-25 | 2009-09-30 | Us Gov Health & Human Serv | PURE NUCLEOSIDES |
HUP0203976A3 (en) * | 2002-11-15 | 2004-08-30 | Sanofi Aventis | Adenozine a3 receptors, process for their preparation and pharmaceutical compositions containing them |
US7825126B2 (en) | 2004-09-09 | 2010-11-02 | The United States Of America As Represented By The Department Of Health And Human Services | Purine derivatives as A3 and A1 adenosine receptor agonists |
KR20080076382A (ko) * | 2007-02-15 | 2008-08-20 | (주)아모레퍼시픽 | 실로스타졸의 제어방출 제제 및 그 제조방법 |
KR101396092B1 (ko) | 2007-03-07 | 2014-05-15 | 미합중국 정부, 디파트먼트 오브 헬쓰 앤드 휴먼 써비스 내셔널 인스티투트 오브 헬쓰 | 아데노신 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 염증성 질환의 예방 및 치료용 약학적 조성물 |
US9018371B2 (en) * | 2007-03-07 | 2015-04-28 | Fm Therapeutics Co., Ltd. | Adenosine derivatives, method for the synthesis thereof, and the pharmaceutical compositions for the prevention and treatment of the inflammatory diseases containing the same as an active ingredient |
KR101207755B1 (ko) * | 2010-02-02 | 2012-12-03 | 이화여자대학교 산학협력단 | 염증성 질환의 예방 및 치료용 약제학적 조성물 |
US20170216244A1 (en) * | 2014-03-06 | 2017-08-03 | Yale University | Methods for treating diabetic nephropathy |
KR101820909B1 (ko) | 2017-07-07 | 2018-01-23 | 퓨쳐메디신 주식회사 | 아데노신 유도체를 포함하는 만성신장질환 예방 및 치료용 약학적 조성물 |
-
2017
- 2017-07-07 KR KR1020170086703A patent/KR101820909B1/ko active IP Right Grant
-
2018
- 2018-07-06 CN CN201880045444.3A patent/CN110869030B/zh active Active
- 2018-07-06 JP JP2020500619A patent/JP6965429B2/ja active Active
- 2018-07-06 EP EP18827831.1A patent/EP3650029B1/en active Active
- 2018-07-06 AU AU2018297009A patent/AU2018297009B2/en active Active
- 2018-07-06 WO PCT/KR2018/007717 patent/WO2019009674A1/ko unknown
- 2018-07-06 CA CA3069118A patent/CA3069118C/en active Active
- 2018-07-06 CN CN202410170774.2A patent/CN118001283A/zh active Pending
- 2018-07-06 US US16/618,396 patent/US11266644B2/en active Active
- 2018-07-06 EP EP23178716.9A patent/EP4234021A3/en active Pending
-
2021
- 2021-10-20 JP JP2021171570A patent/JP2022017355A/ja active Pending
-
2022
- 2022-01-26 US US17/585,497 patent/US20220143017A1/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101323413B1 (ko) * | 2012-07-26 | 2013-10-29 | 이화여자대학교 산학협력단 | (2r,3r,4s)-2-(2-클로로-6-(3-아이도벤질아미노)-9h-퓨린-9-일)-테트라하이드로싸이오펜-3,4-다이올 및 이의 유도체를 포함하는 만성신장질환 예방 또는 치료용 약학적 조성물 |
Non-Patent Citations (1)
Title |
---|
石戸谷 滋人ほか, 日本泌尿器科学会雑誌, vol. 94, no. 7, JPN6020048875, 2003, pages 645 - 655, ISSN: 0004520993 * |
Also Published As
Publication number | Publication date |
---|---|
WO2019009674A1 (ko) | 2019-01-10 |
CN118001283A (zh) | 2024-05-10 |
EP4234021A3 (en) | 2023-09-27 |
JP2022017355A (ja) | 2022-01-25 |
US11266644B2 (en) | 2022-03-08 |
US20220143017A1 (en) | 2022-05-12 |
EP4234021A2 (en) | 2023-08-30 |
EP3650029B1 (en) | 2023-06-28 |
EP3650029A4 (en) | 2021-05-05 |
JP6965429B2 (ja) | 2021-11-10 |
CN110869030B (zh) | 2024-03-01 |
AU2018297009B2 (en) | 2021-10-07 |
EP3650029A1 (en) | 2020-05-13 |
US20200289511A1 (en) | 2020-09-17 |
CA3069118C (en) | 2022-05-31 |
CA3069118A1 (en) | 2019-01-10 |
AU2018297009A1 (en) | 2020-03-05 |
CN110869030A (zh) | 2020-03-06 |
KR101820909B1 (ko) | 2018-01-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6965429B2 (ja) | アデノシン誘導体を含む糖尿病性腎症の予防及び治療用薬学的組成物 | |
Erdmann et al. | Pioglitazone and mechanisms of CV protection | |
US9572801B2 (en) | Tetrahydronaphthyridinyl propionic acid derivatives and uses thereof | |
WO2013043925A1 (en) | Sodium channel blockers reduce glucagon secretion | |
KR101848121B1 (ko) | 통풍 발열의 치료법 | |
JP2016512201A (ja) | 急性腎障害の治療方法 | |
WO2012159107A1 (en) | Inhibition of renal fibrosis | |
US20080027052A1 (en) | Methods for treating cystic kidney disease | |
JP5800368B2 (ja) | 非アルコール性脂肪性肝炎の予防及び/又は治療剤 | |
KR101848122B1 (ko) | 환자 부분모집단에서의 통풍 치료 방법 | |
Rosner | The pathogenesis of susceptibility to acute kidney injury in the elderly | |
US20140045889A1 (en) | Combination Drug Containing Probucol and a Tetrazolyalkoxy-Dihydrocarbostyril Derivative With Superoxide Supressant Effects | |
US10143666B2 (en) | Small molecule inhibitors targeting CAG-repeat RNA toxicity in polyglutamine diseases | |
WO2022048618A1 (en) | Methods to treat inflammatory bowel disease | |
KR102671944B1 (ko) | Pbc 의 치료제 | |
US20020115661A1 (en) | Method for treating chronic obstructive pulmonary disease | |
JP2019059673A (ja) | Pbcの治療剤 | |
JP2010013441A (ja) | 過活動膀胱治療剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200217 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200217 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20201222 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210315 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210608 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210811 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210921 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20211020 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6965429 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |